PDF Cover

Benralizumab Market

The market for Benralizumab was estimated at $1.2 billion in 2024; it is anticipated to increase to $2.1 billion by 2030, with projections indicating growth to around $3.3 billion by 2035.

Report ID:DS1802493
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Benralizumab
Share
Connect
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Benralizumab Market Outlook

Revenue, 2024

$1.2B

Forecast, 2034

$3.0B

CAGR, 2025 - 2034

9.7%

The Benralizumab industry revenue is expected to be around $1.3 billion in 2025 and expected to showcase growth with 9.7% CAGR between 2025 and 2034. Benralizumabs importance today cannot be underestimated as it steadily gains traction in the pharmaceutical markets due to factors like enhanced effectiveness and fewer side effects than other treatments available in the market and a rising demand influenced by the increasing occurrence of conditions, like severe asthma that this medication addresses. The drug remains significant due to its connection with the healthcare sectors search for better treatment choices and the persistent need, for medications that enhance patient results effectively.

Benralizumab stands out as a monoclonal antibody therapy that can attach to the IL 5 receptor found on eosinophils and basophils cells for treatment purposes. One prominent use of this treatment is for severe cases of eosinophilic asthma and other related conditions involving eosinophils. Recent trends indicate a growing interest and demand for targeted therapies like Benralizumab due to their encouraging outcomes; thus sparking enthusiasm, for the potential advantages offered by personalized medicine and advanced biological treatments.

Benralizumab market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Benralizumab Market Outlook

Market Key Insights

  • The Benralizumab market is projected to grow from $1.2 billion in 2024 to $3.0 billion in 2034. This represents a CAGR of 9.7%, reflecting rising demand across Severe Asthma Treatment, Chronic Obstructive Pulmonary Disease (COPD), and Hypereosinophilic Syndrome.

  • AstraZeneca PLC, GlaxoSmithKline PLC, and Novartis AG are among the leading players in this market, shaping its competitive landscape.

  • U.S. and UK are the top markets within the Benralizumab market and are expected to observe the growth CAGR of 7.1% to 10.2% between 2024 and 2030.

  • Emerging markets including Colombia, Malaysia and UAE are expected to observe highest growth with CAGR ranging between 9.3% to 12.1%.

  • Transition like Adoption in Severe Asthma Treatment is expected to add $229 million to the Benralizumab market growth by 2030

    .

  • The Benralizumab market is set to add $1.8 billion between 2024 and 2034, with manufacturer targeting Chronic Obstructive Pulmonary Disease & Eosinophilic Granulomatosis with Polyangiitis Application projected to gain a larger market share.

  • With Advancements in biotechnology, and increase in Respiratory Disorders, Benralizumab market to expand 152% between 2024 and 2034.

benralizumab market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Benralizumab - Country Share Analysis

Opportunities in the Benralizumab

The growing need for treatments and the changing competitive landscape underscore the importance of partnerships between pharmaceutical companies and research institutions in strategic planning and development efforts. Collaborating on Benralizumab could also lead to the discovery of treatment possibilities improvements, in drug design and acceleration of clinical trial processes.

Growth Opportunities in North America and Europe

In North America's healthcare landscape is where Benralizumab shines for its effectiveness in treating asthma cases is acknowledged widely and valued highly by healthcare professionals and patients alike for its positive impact in managing severe asthma symptoms effectively The established pharmaceutical industry and top notch healthcare services play a crucial role in driving the demand for Benralizumab within the region Further fuel to the fire comes from the high prevalence of asthma cases growing government efforts to combat asthma and increased healthcare expenditure which together steer the market for Benralizumab in North America Despite these favorable conditions competition from other treatment options and the expensive nature of Benralizumab therapy could be obstacles to sustained growth, in this part of the world.
In comparison to regions like Europe where the healthcare system is well established and there is a focus on research and development investments in place; it creates a favorable setting for Benralizumab to flourish and gain acceptance among the population suffering from severe asthma due to increased awareness about the condition and the effectiveness of treatments like Benralizumab that are available. The market growth is further propelled by these factors. However the presence of regulatory measures and strong competition from other medications may pose challenges, for Benralizumabs expansion in this region. To promote the adoption of Benralizumab, in Europe. It is recommended that government and healthcare organizations develop plans to guarantee the availability of cost easily accessible treatment choices.

Market Dynamics and Supply Chain

01

Driver: Advancements in Biotechnology, and Favourable Regulatory Policies

Recent progressions in biotechnology have also significantly boosted the development of biologic therapies such as Benralizumab which is also widely employed to address eosinophilic asthma cases. The ongoing enhancements within the biotechnology field are also anticipated to not only enhance the precision and effectiveness of these treatments but also contribute to a surge 𓃵n demand for this particular drug, within the market.

Supportive regulatory policies towards approval and commercialization of innovative drugs like Benralizumab are also pivotal for the growth of its market. This fosters a conducive environment for further research, developments, and sale of the drug, boosting its market expansion.

The increase in ailments globally has also created a demand for practical remedies to address the issue effectively. Benralizumabs effectiveness in easing asthma plays a significant part in meeting this need and presents a hopeful strategy, for tackling respiratory conditions.

02

Restraint: High Cost of Benralizumab

The expensive price of Benralizumab. A medication for asthma that boosts the immune system. Might hinder market expansion efforts since the high costs discourage potential consumers and worsen healthcare accessibility discrepancies. This situation ultimately lowers demand, for the drug. Adversely impacts its market performance.

03

Opportunity: Investing in Technology-Driven Applications and Exploring Untapped Markets

The rapid progress in technology has the potential to enhance drug delivery systems to be more effective and user friendly for patients benefit. Enhancing its effectiveness. Increasing patient compliance can be achieved by integrating technological innovations, like smart inhaler devices or nanotechnology based drug delivery systems into Benralizumab applications. Technology also plays a role in minimizing wastage and reducing adverse effects to improve the overall outcomes of treatment plans.

Despite the progress made in medicine today many places around the world still lack access to advanced treatments like Benralizumab. Regions like Asia, Africa and the Middle East continue to see cases of severe eosinophilic asthma, which is one of the main uses of Benralizumab. Therefore these untapped markets present an opportunity, for growth that could increase the adoption and sales of Benralizumab.

04

Challenge: Lack of Awareness and Knowledge

Another to the Benralizumab market is the lack of awareness and knowledge about this particular medication. Despite advances in the medical field, there are regions, particularly in lower-income countries, where up-to-date knowledge about such specialized treatments is not only widely disseminated. This unawareness directly affects the market demand by limiting the potential number of users, thereby acting as a in the market growth of Benralizumab.

Supply Chain Landscape

1

Raw Material Procurement

Eli Lilly and CompanyPfizer
2

Drug Development & Production

AstraZenecaGlaxoSmithKline
3

Distribution & Logistics

McKesson CorporationAmerisourceBergen
4

Retail & End-Use Industry

Hospital PharmaciesRetail PharmaciesOnline Pharmacies
Benralizumab - Supply Chain

Use Cases of Benralizumab in Severe Asthma Treatment & Chronic Obstructive Pulmonary Disease (COPD)

Severe Asthma Treatment : Benralizumab is a trusted medication for severe eosinophilic asthma treatment, primarily administered in reducing exacerbations and promoting better lung function. This of Benralizumab directly targets and reduces eosinophils in the blood, hence providing relief for patients. Top players, such as AstraZeneca, have been leading in this application, known for their promising results and strong market position.
Chronic Obstructive Pulmonary Disease (COPD) : In COPD management, Benralizumab has shown efficacious results. This monoclonal antibody is utilized to reduce annual exacerbation rates in COPD patients, significantly improving their health status. Firms like GlaxoSmithKline and Novartis boast robust portfolios and hold a prominent market position in this application.
Hypereosinophilic Syndrome : Benralizumab is proving to be a potential candidate in the treatment of Hypereosinophilic Syndrome, a rare, debilitating condition. By mitigating eosinophils, it provides symptomatic relief for patients, underscoring its versatility. In this application, pioneering companies like Sanofi and Pfizer have a commanding presence, marked by their expansive reach and positive patient outcomes.

Recent Developments

Benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, has seen significant advancements in recent market developments. The increasing prevalence of severe asthma and respiratory disorders globally has heightened the demand for efficacious treatment modalities, consequently driving the Benralizumab market expansion.

December 2024 : AstraZeneca, the leading provider of Benralizumab, launched a robust digital campaign to increase market awareness of the drugs benefits in asthma-related treatments.
September 2024 : Clinical trials for a novel application of Benralizumab for severe hypereosinophilic syndrome were initiated by AstraZeneca, showcasing potential for the broadening of Benralizumabs therapeutic uses.
June 2024 : AstraZeneca secured FDA approval to expand the use of Benralizumab for the treatment of Nasal Polyposis, indicating a strategic shift towards non-asthma related applications.

Impact of Industry Transitions on the Benralizumab Market

As a core segment of the Pharmaceutical industry, the Benralizumab market develops in line with broader industry shifts. Over recent years, transitions such as Adoption in Severe Asthma Treatment and Recognition as Hypereosinophilic Syndrome Solution have redefined priorities across the Pharmaceutical sector, influencing how the Benralizumab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Adoption in Severe Asthma Treatment

Benralizumab has been making progress in the field of treating severe asthma lately by targeting eosinophils effectively. A of white blood cell closely linked to the asthmatic reaction. It stands out as an interleukin 5 receptor alpha directed cytolytic monoclonal antibody. In the past treatment for asthma mainly revolved around corticosteroids and basic inhalants. The arrival of Benralizumab offers a more tailored approach to combating the condition with fewer side effects, on the whole body. This shift in therapy has led to advancements in tailored medicine. Is paving the way for improved patient results as Benralizumab gains greater acceptance, among healthcare providers and patients alike.

02

Recognition as Hypereosinophilic Syndrome Solution

Another significant transition in the pharmaceutical landscape is Benralizumab’s growing recognition for its crucial role in treating hypereosinophilic syndrome, a complex group of conditions characterized by persistently elevated eosinophil levels. These elevated eosinophils trigger widespread inflammation and cause damage across multiple body tissues. The drug’s targeted mechanism of action in reducing eosinophils has positioned it as a highly effective digital therapeutic solution, driving its adoption and reinforcing its importance in advanced respiratory and immune disorder management.